ANRS, Emerging Infectious Diseases
241
19
29
118
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
6.2%
15 terminated/withdrawn out of 241 trials
88.7%
+2.2% vs industry average
19%
45 trials in Phase 3/4
8%
9 of 118 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (241)
Prospective Cohort of People Starting Treatment for Tuberculosis Disease in France (FrenchTB)
Role: lead
Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir
Role: lead
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load
Role: lead
Reducing Antiretroviral Treatments
Role: lead
A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults
Role: lead
Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4
Role: lead
Efficacy of Ultraviolet Germicidal Irradiation Devices to Reduce Respiratory Infections in Nursing Homes: Cluster Randomized Crossover Trial
Role: collaborator
An Experimental Medicine Multicenter Trial to Evaluate the Safety and Immunogenicity of Experimental Versus Authorized SARS-CoV-2 Vaccine Candidates as a Booster Dose in Healthy Participants Previously Vaccinated With Authorized mRNA SARS-CoV-2 Vaccines.
Role: lead
ARN-75039 Lassa Fever Treatment in West Africa
Role: collaborator
Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease
Role: lead
Assessment of Immune Memory - Humoral and Cellular - in mPOX-infected Patients : an Ancillary Study of the ANRS0258s MOSAIC Cohort
Role: lead
Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers
Role: lead
Residual Replication of HIV-1 in the Gut Associated Lymphoid Tissue (GALT) of Patients on Highly Active Antiretroviral Therapy (HAART): the ANRS EP 44 Study
Role: lead
Gut-Associated Lymphocyte Trafficking
Role: lead
X-linked Biological Response to HIV Sensing: the ANRS EP 53 Study
Role: lead
Access to PrEP for MSM: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP)
Role: lead
Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot Study
Role: lead
Human Papillomavirus Infection and Related Anal Lesions in HIV-positive Men Who Have Sex With Men
Role: lead
Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence
Role: lead
Drug Use & Infections in ViEtnam: Mental Health Intervention for INjecting Drug Users
Role: lead